CAPR FY2025 EPS Forecast Raised by Cantor Fitzgerald

Capricor Therapeutics Inc (NASDAQ:CAPR) – Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for Capricor Therapeutics in a report issued on Tuesday, April 1st. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings per share of ($1.11) for the year, up from their previous forecast of ($1.39). Cantor Fitzgerald currently has a “Overweight” rating and a $30.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Separately, HC Wainwright reissued a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday, March 17th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $9.74 on Thursday. Capricor Therapeutics has a 1 year low of $3.52 and a 1 year high of $23.40. The company has a market cap of $444.88 million, a P/E ratio of -9.19 and a beta of 4.09. The stock’s fifty day moving average price is $13.72 and its 200-day moving average price is $15.03.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The company had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million.

Institutional Trading of Capricor Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Farallon Capital Management LLC purchased a new position in Capricor Therapeutics in the fourth quarter worth about $31,056,000. Vanguard Group Inc. boosted its holdings in shares of Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after buying an additional 700,243 shares during the last quarter. Woodline Partners LP bought a new stake in Capricor Therapeutics during the fourth quarter valued at approximately $8,693,000. Altium Capital Management LLC increased its holdings in Capricor Therapeutics by 150.5% during the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock valued at $9,853,000 after buying an additional 429,000 shares during the last quarter. Finally, Black Diamond Financial LLC purchased a new stake in Capricor Therapeutics during the fourth quarter valued at approximately $3,833,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.